Medicare raised premiums late last year in preparation to cover the drug Aduhelm. Ultimately, Medicare rejected coverage of the drug, with limited exceptions.

Government insurer won’t cover Aduhelm’s $28,000-a-year price tag except for clinical trials.

The cost of the newly approved treatment will be about $56,000 a year, much of it paid for by Medicare.